Physician profile
Scott Picou
NPI 1346506821
$7,511.60
in general payments reported to CMS, 2019-2025
55 companies · $1,195 in 2025
The $1,195 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $982 · 2020: $858 · 2021: $1,491 · 2022: $936 · 2023: $1,155 · 2024: $893 · 2025: $1,195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,243.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,051.75 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $728.15 | 2019-2025 | |
| Amgen INC. | $566.44 | 2019-2024 | Repatha, Otezla, Evenity |
| Janssen Pharmaceuticals, INC | $510.44 | 2019-2025 | Spravato |
| Abbott Laboratories | $433.09 | 2021-2023 | Jot Dx, Freestyle Libre |
| Pfizer INC. | $321.33 | 2019-2025 | |
| Allergan, INC. | $308.31 | 2019-2020 | |
| Amarin Pharma, INC. | $280.56 | 2020-2022 | |
| Novo Nordisk INC | $280.47 | 2019-2024 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $229.89 | 2019-2024 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $214.05 | 2020-2025 | Xifaxan |
| Bardy Diagnostics, INC. | $185.73 | 2019-2020 | |
| Daiichi Sankyo INC. | $167.29 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $163.65 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $146.86 | 2025 | Caplyta |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Picou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.